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A
Vav
ABSTRACT The protooncogenic protein Vav has the
structure of an intracellular signal transducer. It is exclusively
expressed in cells of hematopoietic lineage and plays a crucial
role in hematopoietic cell differentiation. Here we report that
both in cell extracts and within intact mammalian cells Vav
binds to Grb2 (Sem-5/ASH/Drk), an adaptor molecule which
plays a key role in Ras activation. The interaction became
evident from a yeast two-hybrid screen and its specificity was
demonstrated by in vitro binding assays. It is mediated by an
unusual protein-protein binding reaction: dimerization of spe-
cific intact Src homology 3 domains of each of the partners.
Signaling during hematopoietic lineage differentiation may
therefore involve the tissue-specific signal transducer Vav
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Intracellular signal transduction pathways play crucial roles
in all decisions about cell development and function. A key
step in the relay of signals from membrane receptors is
performed by a group of proteins which exchange guanine
nucleotides on Ras and its close relatives (1). Some of these
factors are specifically expressed in certain cell lineages,
where they may be mediators ofdifferentiation and functional
specialization (reviewed in ref. 2). The protooncogenic pro-
tein Vav (3-6) is a candidate lineage-specific mediator in that
it is expressed only in cells of the hematopoietic lineages (3,
7). It contains multiple structural motifs commonly used by
intracellular signaling molecules, including Src homology 2
and 3 (SH2 and SH3) and pleckstrin homology (PH) domains
as well as an acidic CDC24 homology region, and a region
homologous to the diacylglycerol (DAG) binding site of
protein kinase C (Fig. 1A). Vav binds to tyrosine-
phosphorylated intracellular tails of cell surface receptors
through its SH2 domain and is itself phosphorylated on
tyrosine after activation of hematopoietic cells through their
surface receptors (8-11). Blocking vav expression with an-
tisense transcripts completely abolishes hematopoietic lin-
eage development in embryonic stem cell cultures (12),
indicating the importance of the Vav signaling pathway
during the differentiation of hematopoietic cells. It has been
suggested that Vav may activate Ras through its ability to
exchange GDP for GTP (13, 14), despite the fact that CDC24,
to which Vav bears sequence homology, is an activator of
Rho, not Ras (reviewed in ref. 1). Truncating an N-terminal
segment of Vav converts it into an oncogenic protein (3, 15,
16).
To study the signaling mechanism controlling hematopoi-
etic development, we have searched for proteins bound to
Vav, using the yeast two-hybrid approach (17-20). We iden-
tified one Vav-associated protein as the adaptor molecule
Grb2 (Sem-5/ASH/Drk) (21-24). Its interaction with Vav
Clone Vc3, Vc7
149 217
Clone Vc8 158 217
FIG. 1. Vav and Grb2 structures and clones isolated from the
yeast two-hybrid system. (A) Domain structure of Vav. Arrow
indicates a breakpoint which greatly increases its transforming
activity (3). pEG/VavC' is the yeast expression plasmid which
encodes the C terminus of Vav and was used for two-hybrid cloning.
E. coli expression plasmids pGEX-Vav/N-SH3 and pGEX-Vav/
SH2-C-SH3 produced glutathione S-transferase (GST)-Vav fusion
proteins for filter binding assays. (B) Partial Grb2 clones isolated
from the HeLa cell expression library are compared with full-length
Grb2. Two clones (Vc3 and Vc7) started from a common amino acid
within the SH2 domain; Vc8 started from a region between the SH2
and C-terminal SH3 domains.
involves an SH3/SH3 interaction. This finding suggests that
Vav is part of a hematopoietic lineage-specific signaling
mechanism that can link to a ubiquitous signal transduction
pathway.
MATERIALS AND METHODS
Yeast Two-Hybrid Cloning. The two-hybrid cloning system
developed by R. Brent and colleagues was used in this study
(18, 19). The yeast expression plasmid pEG/VavC' (Fig. 1A)
was constructed as follows: plasmid pBSK-mVav.10 (6)
(generously provided by J. M. Adams) was cleaved with
restriction endonuclease Nco I (at a murine vav internal site)
andXho I (at a site present in the pBluescript multiple cloning
region 3' to vav sequence); the 0.84-kb DNA fragment
encoding the C terminus of Vav protein was purified and
ligated into EcoRI- and Xho I-digested yeast expression
Abbreviations: GST, glutathione S-transferase; SH2 and SH3, Src
homology 2 and 3; HA, hemagglutinin.
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vector pEG202 (19) together with an EcoRI-Nco I adaptor to
restore the opening reading frame. A yeast expression library
derived from HeLa cell cDNA was generously provided by
R. Brent (19) and screened as described (20). Sequence
analysis was performed with a Sequenase kit (United States
Biochemical) according to the manufacturer's instructions.
Generation of GST Fusion Proteins and Biotinylation of
Probes for in Vitro Binding Assays. Most GST-Vav fusion
protein expression vectors were prepared by ligating various
restriction fragments of vav (illustrated in Fig. 3A) into
Escherichia coli expression plasmid pGEXlZT (these includ-
ing GST-Vav/N-SH3, GST-Vav/SH2-(C-SH3), GST-
VavB, GST-VavD, and GST-VavE) or pGEX2T (GST-
VavF; see Fig. 3A). GST-VavPA expression plasmid was
made by inserting a synthetic vav fragment encoding amino
acids 603-622 (YYGIPPPPGAFGPFLRLNPG) into
pGEXlZT. Expression plasmids for GST-Grb2/C-SH3,
GST-Grb2/C-SH3N'Del, and GST-Grb2/C-SH3C'Del were
made by subcloning polymerase chain reaction (PCR)-
amplified Grb2 sequences into pGEXlZT. GST-Grb2/C-
SH3 is GST fused to an intact C-terminal SH3 domain ofGrb2
(amino acids 158-217), GST-Grb2/C-SH3N'Del is GST
fused to an N-terminally truncated SH3 of Grb2 (amino acids
170-217), and GST-Grb2/C-SH3C'Del is GST fused to C-ter-
minally truncated SH3 of Grb2 (amino acids 158-204). Syn-
thesis of GST fusion proteins was induced with 0.2 mM
isopropyl ,B-D-thiogalactopyranoside during the midlogarith-
mic phase of bacterial growth (OD600 of 0.5). After 2 hr of
induction, bacteria were harvested and lysed. GST fusion
proteins were either affinity purified with glutathione-
conjugated agarose beads (Molecular Probes) or used in
crude form. Purified proteins were quantitated by micropro-
tein assay (Pierce) or by visualizing Coomassie blue-stained
full-length protein bands on SDS/polyacrylamide gels if
proteins were partially degraded. GST fusion proteins were
biotinylated with biotinamidocaproate N-hydroxysuccinim-
ide ester (Sigma).
In Vitro Filter Binding Assay (25, 26). Protein samples were
fractionated by electrophoresis through an SDS/10% poly-
acrylamide gel and transferred to a nitrocellulose membrane
filter. One microgram of protein or equivalent full-length
form (if proteins were partially degraded) was loaded per
lane. After the fiter was blocked with 0.2% gelatin in cold
(4°C) TBST buffer (10mM Tris, pH 8.0/150mM NaCl/0.05%
Tween 20) for 30 min, biotinylated probes (1 ,ug/ml) were
added and incubation continued for 2 hr with gentle shaking.
The filters were washed with cold TBST four times (5 min per
wash). Streptavidin-conjugated alkaline phosphatase (Boeh-
ringer Mannheim) was diluted 1:5000 with 0.2% gelatin/
TBST and incubated with the filter for 1 hr at 4°C (with gentle
shaking) and washed as described above. Blots were devel-
oped with nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl
phosphate (Promega) at room temperature in 100 mM Tris,
pH 9.5/100 mM NaCl/5 mM MgCl2. Reactions were stopped
by changing filters into pure water when background color
started to appear.
Adsorption of Endogenous Vav Protein to Immobilized
GST-Grb2 Proteins. GST fusion proteins were produced in E.
coli and crude bacterial lysates were mixed with glutathione-
conjugated agarose beads for 1 hr. Sufficient bacterial lysate
was used to ensure that the binding sites on the glutathione
beads were saturated by the GST or GST-Grb2 fusion
proteins. After extensive washes with cold (4°C) phosphate-
buffered saline, 20 ,ul (bed volume) of protein-bound beads
was added to cytosolic cell extracts containing 3 mg of
protein in lysis buffer [20 mM Hepes, pH 7.4/150 mM
NaCl/10% (vol/vol) glycerol/1% (vol/vol) Triton X-100/1
mM EGTA/1.5 mM MgCl2/10 mM NaF/1 mM Na3/VO4/1
mM phenylmethylsulfonyl fluoride with aprotinin (10 ,ug/ml)
and leupeptin (10 ,ug/ml)]. Incubation was continued at 4°C
for 4 hr with end-to-end rotation. The beads were washed
four times with lysis buffer and suspended in 2x SDS gel
loading buffer (0.1 mM Tris, pH 6.8/20% glycerol, 2%
SDS/0.01% bromophenol blue/5% 2-mercaptoethanol). Af-
ter boiling for 5 min, the eluted proteins were analyzed by
SDS/PAGE and electrotransferred to nitrocellulose filter.
The filter was blotted with a monoclonal anti-Vav antibody
(Upstate Biotechnology, Lake Placid, NY). Horseradish
peroxidase-conjugated goat anti-mouse Fc antibody (Pierce)
was used as secondary antibody and blots were developed
with ECL reagents (Amersham).
Establishment of a Vav/Grb2-Expressing 3T3 Cefl Line.
Retroviral expression construct pGD/HAVavF was made by
ligating full-length Vav cDNA into vector pGD; an oligonu-
cleotide encoding influenza hemagglutinin (HA) epitope was
inserted in-frame at the 5' end of the vav gene. Grb2 expres-
sion construct pBABEGrb2myc was a generous gift from
R. A. Weinberg (27). Retroviral stocks were produced for
both plasmids and used to infect NIH 3T3 cells (28). Clones
were selected with G418 and puromycin, and protein expres-
sion was detected by Western analysis.
Coimmunoprecipitation ofVav and Grb2 from Cell Lysates.
VG5/3T3 cells, which express HA-tagged Vav and Myc-
tagged Grb2 proteins, were grown in 150-mm culture plates
to near confluency and harvested. For each immunoprecip-
itation, 20 plates were used. The immunoprecipitation was
performed as described earlier (20), using monoclonal an-
ti-HA antibody (12CA5) or anti-Myc antibody (9E10). Im-
munoprecipitates were analyzed by Western blotting using
either anti-Vav antibody or anti-Grb2 antibody. Secondary
reagents were either goat anti-rabbit antibody conjugated to
alkalian phosphatase (Boehringer Mannheim) or 1251-labeled
protein A (Amersham).
RESULTS
The C terminus of Vav was subcloned into the yeast expres-
sion vector pEG202, which was designed for yeast two-
hybrid interaction cloning (17-19). The full length Vav-LexA
fusion protein had a weak transcriptional activity, precluding
its use as a suitable "bait," but the LexA-Vav C-terminus
fusion gave no basal activity. This portion ofVav includes its
SH2 domain flanked by two SH3 domains (Fig. 1A), which
are structures commonly used for protein-protein interac-
tions by signaling molecules (29, 30). This construct (pEG/
VavC') was used to screen a yeast expression library derived
from the cDNA of HeLa cells. Two million clones were
screened, and 18 clones were selected. These clones con-
ferred galactose-dependent phenotypes indicating protein
interaction on yeast strain EGY48, and the phenotypes
segregated with the plasmids from the cDNA library. Thus,
these cDNAs represented candidates encoding Vav-binding
proteins.
Six cDNA clones were randomly selected from the positive
pool from the HeLa library and were subjected to sequence
analysis. Nucleotide sequences of three clones showed a
100% match to the cDNA ofhuman Grb2 (Sem-5/ASH/Drk)
(21-24), a ubiquitously expressed adaptor molecule involved
in the Ras activation pathway (reviewed in ref. 31). Grb2
cDNA thus represented about 50% of the Vav-interacting
molecules isolated from HeLa cells. The other three cDNAs
contained proline-rich sequences which probably were bind-
ing sites for Vav SH3 domains. Of the three Grb2 partial
cDNAs, two (Vc3 and Vc7) had identical fusion junctions
with LexA and probably represented the same original plas-
mid in the library, while the other one (Vc8) contained a
slightly shorter Grb2 sequence (Fig. 1B). All three clones
contained an intact C-terminal SH3 domain (C-SH3) of the
Grb2 protein.
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We used an in vitro filter binding assay (25, 26) to confirm
the interaction between Grb2 and Vav and to map the
structural domains responsible for the interaction. The N-ter-
minal SH3 domain (N-SH3) and the SH2-(C-SH3) region of
Vav were separately expressed as GST fusion proteins in E.
coli (pGEX-Vav/N-SH3 and pGEX-Vav/SH2-C-SH3 in Fig.
1B) and affinity purified. Approximately 1 pg of each fusion
protein was electrophoresed through an SDS/polyacryl-
amide gel, transferred to a nitrocellulose filter, and blotted
with biotinylated GST-Grb2/C-SH3 fusion protein. The
Grb2 C-terminal SH3 domain bound with high affinity to the
N-terminal-SH3 domain ofVav (Fig. 2). The specificity ofthe
interaction in this assay was demonstrated by the inability of
Grb2/C-SH3 to bind to Vav/SH2-C-SH3 or to either SH3
domain of Grb2 (Fig. 2). Since both Vav and Grb2 seemed to
be binding via SH3 domains, we expanded the test for binding
specificity by using an additional nine biotinylated GST-SH3
fusion proteins as probes in an attempt to show binding to any
of the four SH3 domains present in Vav and Grb2. These
probes were Grb2/N-SH3, Abl/SH3, Src/SH3, neural Src/
SH3, Lyn/SH3, Fyn/SH3, Lck/SH3, Hck/SH3, and Btk/
SH3. Although all the probes were able to bind to their
specific cognate proline-rich peptides, none ofthem bound to
any of the four SH3 domains in Vav and Grb2 (data not
shown). Of the total of 38 combinations of SH3 domains
tested for binding, only the Vav N-terminal SH3 domain and
the Grb2 C-terminal SH3 domain specifically interacted with
each other. Thus, Vav/Grb2 binding is a highly specific
interaction between SH3 domains.
SH3 binding sites are generally short, linear, proline-rich
peptide motifs (20, 26, 32). The only such candidate sequence
was a continuous run of four prolines in the N-terminal SH3
domain of Vav (Fig. 3A). However, when we truncated the
Vav N-terminal-SH3 domain and tested its abilities to bind to
co
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FIG. 2. Mapping of interacting domains of Vav and Grb2 with in
vitro filter binding assays. Various segments of Vav and Grb2 were
cloned into pGEX vectors and produced as GST fusion proteins in E.
coli. These included Vav's N-terminal SH3 domain (GST-Vav/N-
SH3; lane 1), Vav's SH2 and C-terminal SH3 domains (GST-Vav/
SH2-C-SH3; lane 2), Grb2's N-terminal SH3 domain (GST-Grb2/N-
SH3; lane 3), and Grb2's C-terminal SH3 domain (GST-Grb2/C-SH3;
lane 4). The Vav sequences in GST fusion proteins are illustrated in
Fig. 1A. One microgram of purified protein for each sample was
subject to SDS/polyacrylamide gel electrophoresis and transferred to
a nitrocellulose filter. Biotinylated GST-Grb2/C-SH3 (1 pg/ml) was
used as probe to detect the binding.
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FIG. 3. Defining structural requirements for Vav/Grb2 interac-
tion (A) Vav sequences present in various GST-Vav fusion proteins.
(B) GST-Vav fusion proteins (indicated on top of each lane) were
blotted onto filters and tested for their ability to interact with the
biotinylated GST-Grb2/C-SH3 domain probe. Each lane contained
1 pg of purified GST fusion protein, except for GST-VavPA (lane 7).
In lane 7, a crude bacterial lysate was used that contained >1 pg of
fusion protein as judged by Coomassie blue staining. Molecular size
markers (kDa) are at left. (C) Nitrocellulose filter strips were blotted
with 1 pg of GST-Vav/N-SH3 and were probed with biotinylated
GST-Grb2/C-SH3 (lane 1), GST-Grb2/C-SH3N'Del (containing the
Grb2 C-terminal SH3 domain truncated from its N terminus) (lane 2),
or GST-Grb2/C-SH3C'Del (containing the Grb2 C-terminal SH3
domain truncated from its C terminus). Molecular size markers (kDa)
are at left.
an intact Grb2 C-terminal SH3 domain, none of the GST-
truncated Vav proteins was able to detectably interact with
Grb2 (Fig. 3 A and B). In particular, fragments containing the
tetraproline sequence did not bind to Grb2. It appears that an
intact N-terminal SH3 domain of Vav is required for Grb2
interaction, although it remains likely that the tetraproline
element plays a role.
We then tested whether Grb2's C-terminal SH3 domain
needs to be intact for binding. We truncated this domain from
both N- and C-terminal ends and made GST fusion proteins.
The intact and deleted Grb2/C-SH3 GST fusion proteins
were biotinylated and used to bind to an intact Vav N-ter-
minal-SH3 domain blotted onto filter paper. The GST fusion
with an intact Grb2 C-terminal SH3 domain bound to Vav,
whereas deletion of 12 or 13 amino acids from either end
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abolished binding (Fig. 3C), indicating that a complete SH3
domain of Grb2 is required for binding to Vav. Thus, the
interaction between the Vav/N-terminal SH3 and Grb2
C-terminal SH3 domain represents another mode of protein
interaction among signal transducers-namely, a highly spe-
cific dimerization of two intact SH3 domains.
To examine whether endogenous full-length Vav protein
binds to full-length Grb2, we prepared cellular lysates from
WEHI-231, a murine B-cell line; murine EL4, a T-cell line;
and 293, a human kidney cell line. The lysates were incubated
with bacterially produced GST-Grb2 proteins immobilized
on agarose beads to assay for Vav binding. After incubation
of beads with the lysates, proteins bound to the beads were
eluted and subjected to Western blot analysis using an
anti-Vav antibody. Both full-length Grb2 and Grb2 C-termi-
nal SH3 domain precipitated endogenous Vav from the
lymphoid cells (Fig. 4A). Truncated Grb2 C-terminal SH3
domains failed to interact with endogenous Vav protein. No
Vav protein was found in the nonhematopoietic cell line 293.
The authenticity of the Vav protein was confirmed with
another anti-Vav antibody (data not shown). These results
showed that the endogenous Vav protein is structurally open
for Grb2 binding and that both proteins in their full-length
form can interact with each other.
A recent report (14) showed that diacylglycerol and phor-
bol esters activate Vav's guanine nucleotide-exchanging ac-
tivity on Ras through a Vav region homologous to the
diacylglycerol binding site in protein kinase C (designated as
the DAG domain in Fig. lA). We tested whether phorbol
ester treatment of cells would affect the binding of Vav to
Grb2. Lysates made from unstimulated and phorbol ester-
treated WEHI-231 cells had comparable amounts of Vav
protein bound to GST-Grb2 (Fig. 4B). Therefore, under the
experimental conditions we used, the Vav/Grb2 interaction
is not affected by phorbol ester activation of the Vav protein.
To investigate whether Vav and Grb2 form complexes in
mammalian cells, we established a 3T3 cell line (VG5/3T3)
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FIG. 5. Vav/Grb2 complex in mammalian cells. Cell lysates
prepared either from NIH 3T3 cells (lanes 1) or from HA-Vav/Grb2-
Myc-expressing 3T3 clone VG5/3T3 (lanes 2 and 3) were immuno-
precipitated with monoclonal anti-HA antibody 12CA5 (lanes 2),
anti-Myc antibody 9E10 (lanes 3), or a mixture of the two antibodies
(lanes 1). Immunoprecipitates were analyzed by Western blotting
using polyclonal anti-Vav antibody (A) or anti-Grb2 antibody (B)
(both from Santa Cruz Biotechnology, Santa Cruz, CA). A longer
exposure of the same blot in B (Lower) shows a contaminating band
in the same position as Grb2, obscuring any possible coimmunopre-
cipitated Grb2.
transfer (28). These cells express Vav protein tagged with the
influenza virus HA epitope and Grb2 protein tagged with a
Myc epitope. Cell lysates from these cells were immunopre-
cipitated with either monoclonal anti-HA or anti-Myc anti-
bodies. The immunoprecipitates were analyzed by Western
blotting using either anti-Vav or anti-Grb2 antibody (Fig. 5).
Some Vav was coimmunoprecipitated by antibody against
Grb2-Myc protein (lane 3). In a control experiment, the
anti-Myc antibody did not precipitate a significant amount of
Vav from WEHI-231 cells, where Vav is highly expressed
(data not shown). When anti-HA antibody was tested for its
ability to coprecipitate Grb2 (lane 2), the experiment was
indeterminate because in an exposure long enough to reveal
a coimmunoprecipitated protein, a contaminating band was
evident at the same position as Grb2 (Fig. SB Lower). Thus,
there is evidence that full-length Vav and Grb2 can form a
complex in mammalian cells.
FIG. 4. Binding of endogenous Vav protein to immobilized
GST-Grb2. (A) Twenty microliters (bed volume) of glutathione-
conjugated agarose beads which were saturated with GST (lanes 1,
6, and 11), GST-full-length Grb2 (lanes 2 and 7), GST-Grb2/C-SH3
(lanes 3, 8, and 12), GST-Grb2/C-SH3N'del (lanes 4 and 9), or
GST-Grb2/C-SH3C'del (lanes 5 and 10) was incubated with WEHI-
231 cell lysates (lanes 1-5), EL4 cell lysates (lanes 6-10), or 293 cell
lysates (lanes 11 and 12). Three micrograms of proteins was used for
each sample. Proteins bound to beads were eluted and analyzed by
Western blotting using a monoclonal anti-Vav antibody (Upstate
Biotechnology). Arrow indicates the position ofVav. Molecular size
markers are at left. (B) A culture of 1.6 x 108 WEHI-231 cells grown
to a density of 5 x 105 per ml was divided in half. Phorbol
12-myristate 13-acetate (PMA, 10 ng/ml; Sigma) was added to one
half and cells were incubated at 37°C for 10 min. Both cell samples
were then harvested and lysed. PMA-stimulated cell lysates (lanes 1
and 2) and unstimulated cell lysates (lanes 3 and 4) were incubated
either with GST (lane 1 and 3) or GST-Grb2/C-SH3 (lanes 2 and 4)
adsorbed to agarose beads. The proteins eluted from the beads were
analyzed as in A.
DISCUSSION
In this study we have demonstrated that the hematopoietic
cell-specific signaling molecule Vav can bind to the ubiqui-
tous adaptor protein Grb2 through a highly specific dimer-
ization of two intact SH3 domains. This interaction first
became evident through a two-hybrid screen in yeast cells
and was then studied in vitro by binding of the Grb2 C-ter-
minal SH3 domain to the Vav SH3 domain immobilized on a
filter. When either SH3 domain was truncated, binding was
abolished. Binding of the full-length proteins was demon-
strated, with GST-Grb2 selecting Vav from cell lysates of
lymphoid cells. Using a 3T3 clone overexpressing both
proteins, we also showed that a Vav/Grb2 complex can form
in mammalian cells.
Vav is a complicated and ambiguous molecule. Its struc-
tural features imply that its SH2 domain should be able to link
the activated tail of a membrane receptor to downstream
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intracellular events through its apparent guanine nucleotide-
exchange function (CDC24 homology). However, Vav also
has the properties of an "adaptor" protein in that it has an
SH3-SH2-SH3 segment as well as a PH domain (Fig. 1A).
Our results suggest that its N-terminal SH3 domain may link
it to Grb2 and thus potentially to an even more extensive
network of interactions. A Sos/Grb2 complex is evident in
many cells (reviewed in ref. 31), and Grb2's N-terminal SH3
domain is mainly responsible for Sos binding (27, 33). Since
Vav binds to Grb2's C-terminal SH3 domain, it may be able
to recruit both Grb2 and Sos into one multiprotein complex.
This ternary protein complex should activate Ras, because
Sos is a strong GDP/GTP exchanger for Ras. This scenario
may explain a puzzle surrounding the biochemical function of
Vav. The CDC24 homology region of Vav should activate
Rho, not Ras, but it has been reported that Vav has GDP/
GTP exchange activity on Ras (13, 14). It is possible that in
those experiments, the Vav contained the Grb2/Sos com-
plex. In fact, it was shown that a protein of -150-kDa, the
molecular size of Sos, could be coimmunoprecipitated by
anti-Vav antibody (13).
The Vav/Grb2 interaction entails an apparently novel
mode of protein/protein interaction through SH3 dimeriza-
tion. Previous cases of SH3 binding (20, 26, 32) have involved
intact SH3 domains associating with a short, linear peptide
containing multiple proline residues. In all of those cases, the
site of SH3 binding could be deleted down to an -10-amino
acid peptide. For the Vav/Grb2 interaction, however, we
were unable to demonstrate binding to structures any shorter
than an intact SH3 domain. The interaction could be similar
to the dimer interface interaction between SH3 and SH2
domains in the Lck molecule (34). The interacting Vav and
Grb2 SH3 domains contain multiple proline residues, so that
the binding might still involve the same specificity of inter-
action seen in other cases, but if that is true, the proline-
containing peptide must be "presented" by the intact SH3
and not by shorter fragments. We have, in fact, identified a
proline-rich substrate to which the Vav N-terminal SH3
domain can bind (data not shown), suggesting that this same
SH3 domain also functions to bind proline-containing se-
quences.
It is interesting that Grb2 can serve as a convergence point
for Ras activation, where various factors send their inputs. In
addition to Vav, signaling molecules such as Shc (35, 36), Abl
(20), Bcr-Abl (37, 38), and IRS-1 (39-41) all bind to Grb2.
Therefore Grb2 may be a focal point for cross talk between
Ras and various signaling pathways. Because Vav is a
molecule limited to hematopoietic cells, it may be that Vav
provides a cell-specific mode of Ras activation appropriate to
the developmental or activation functions of such cells.
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